What AVS Bio does

AVS Bio (legal entity Avian Vaccine Services, LLC) produces Specific Pathogen Free (SPF) eggs and adjacent laboratory biological products, and provides antibody discovery, protein production, and preclinical testing services for the development of biologics. The company operates 20+ facilities across the United States (Connecticut, New York, Illinois, Missouri) and the Netherlands (Utrecht, Oss), serving global biopharma, pharmaceutical, animal health, and diagnostics customers developing vaccines, therapeutics, and assays. Its core technology stack centers on a proprietary rPEx® recombinant protein expression platform using HEK293 and CHO cell lines (10 µg to 150 L scale, 4-week typical turnaround, endotoxin <1 EU/mg), multiple antibody discovery platforms (single B cell, phage display, hybridoma, rare hit magnification), GlymaxX® ADCC-enhancement licensed from ProBioGen, and bi-/multi-specific and VHH antibody production capabilities. The company has supported 10 antibodies that entered clinical trials, produced 23,000+ proteins and 1 billion+ SPF eggs since inception, and holds a 24-year USDA license.

The business model combines catalog product sales (SPF eggs, avian antigens, antisera, recombinant proteins, catalog antibodies with published unit pricing) with quote-based custom services spanning antibody discovery, protein production, cell line development, and preclinical testing. Custom work — including IND-enabling studies now offered via the RoukenBio partnership — is delivered through enterprise B2B direct sales with multi-year contracts, while smaller research customers transact through an online catalog with add-to-cart and quote-request functionality. Revenue mechanics are split between product sales (one-time/recurring catalog purchases) and professional services (custom antibody programs, large-scale protein expression, preclinical studies). The company is a private, PE-backed entity owned by Arlington Capital Partners, having previously operated as a subsidiary of Charles River Laboratories. Approximately 300 employees support operations, with strategic leadership under CEO Jac Price (appointed July 2023) and a European hub led by CSO Ilse Roodink and General Manager Roland Romijn.

Name

AVS Bio

Legal name

Avian Vaccine Services, LLC

Website

https://avsbio.com

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

101–250 employees

Short description

AVS Bio produces Specific Pathogen Free (SPF) eggs and provides antibody discovery, recombinant protein production, and preclinical testing services to global biopharma, pharmaceutical, animal health, and diagnostics customers developing vaccines, therapeutics, and assays.

Ownership category

akta.pro rank

Product category

Biologics Services and Biological Materials

NAICS

Poultry Hatcheries (112340), Poultry and Egg Production (1123)

SIC

Biological Products, (No Disgnostic Substances) (2836), Agricultural Prod-Livestock & Animal Specialties (200)

akta.pro primary industry

Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH)

akta.pro secondary industries

Poultry & Avian Production Veterinary Services (HLAMABAC), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Hatcheries & Chick Production (Day-Old Chicks, Pullets) (AFAEADAD)

Keywords

• SPF egg production
• Avian biologicals supply
• Antibody discovery services
• Recombinant protein expression
• Preclinical antibody testing

Headquarters

HQ city

Norwich

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. SPF Eggs and Avian Biologicals: Sale of Specific Pathogen Free eggs, SPF chickens, chicken cell products, avian antigens, avian antisera, and related biological materials. Core historical business supporting vaccine and biologics manufacturing.
2. Antibodies and Proteins Products: Catalog and custom antibodies, recombinant proteins, and related products sold to research and biopharma customers. Includes products like WNT Surrogate-Fc Fusion Protein, vWF domains, and Alpha-1-antitrypsin.
3. Antibody Discovery and Development Services: Full-service antibody discovery including tool generation, immunization, discovery, characterization, developability profiling, optimization and engineering, cell line development, protein production, and preclinical testing.
4. Protein Production Services: Recombinant protein production using rPEx® platform from research scale to large-scale (up to 150L). Includes bi- and multi-specific antibodies, VHH production, and ADCC-enhanced antibodies.
5. Preclinical Testing Services: IND-enabling preclinical antibody testing through partnership with RoukenBio. Immunology and oncology assays including ADCC, ADCP, CDC, T cell, NK cell, and other immune cell assays.
6. Avian Services: Diagnostic and regulatory testing services, IgY antibodies, and custom biologics/vaccine manufacturing support.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

AVS Bio produces and supplies Specific Pathogen Free (SPF) eggs, avian biologicals (chicken cell products, avian antigens, antisera, IgY antibodies), catalog and custom antibodies, and recombinant proteins to research and biopharma customers. In parallel, the company delivers full-service antibody discovery and development — including tool generation, immunization, discovery, characterization, developability profiling, optimization and engineering, cell line development, protein production, and preclinical testing — to global pharmaceutical, biotechnology, and animal health customers developing vaccines, therapeutics, and diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• rPEx®: Proprietary recombinant protein expression platform using HEK293 and CHO cell lines for high-quality protein production from research to large-scale.
• GlymaxX®

Products and services

• SPF Eggs and Avian Biologicals Specific Pathogen Free eggs and related avian biological materials (including SPF chickens, chicken cell products, avian antigens, avian antisera, mycoplasma/pullorum plate antigens, human influenza virus, Sendai virus, and other avian reagents) supplied to vaccine manufacturers, diagnostics developers, and biopharma companies for biologics production and testing.
• USDA-licensed FFM Products (IgY Antibodies) USDA-licensed IgY antibodies and related avian antibody products supplied for veterinary and human health applications, leveraging AVS Bio's long-standing USDA license and IgY clinical experience (including the company's first IgY clinical study supported in 2020).
• Catalog and Custom Antibodies and Recombinant Proteins Catalog and custom antibodies and recombinant proteins across research areas including organoid research, inflammatory diseases, cell biology, complement/innate immunity, hematology, infectious diseases, molecular cell biology, oncology, and general research tools; produced via the proprietary rPEx® platform and sold to research and biopharma customers (including products like WNT Surrogate-Fc Fusion Protein, vWF domains, and Alpha-1-antitrypsin).
• Antibody Discovery and Development Services Full-service antibody discovery and development program for biopharma and biotechnology customers, covering tool generation, immunization, antibody discovery (single B cell, phage display, hybridoma, rare hit magnification), characterization, developability profiling, optimization and engineering, cell line development, protein production and purification, and preclinical testing.
• Recombinant Protein Production Services (rPEx® Platform) Recombinant protein production service using the proprietary rPEx® platform with HEK293 and CHO cell lines, supporting discovery through large-scale production up to 150 liters with endotoxin levels below 1 EU/mg and a typical 4-week turnaround; includes bi- and multi-specific antibodies (Fc-free formats), VHH antibody production (tag-free), and ADCC-enhanced antibodies via GlymaxX®.
• Preclinical Antibody Testing Services IND-enabling preclinical antibody testing service delivered in partnership with RoukenBio, providing immunology and oncology assays such as ADCC, ADCP, CDC, T cell, NK cell, and other immune cell assays to support lead candidate prioritization and reduce translational risk before IND-enabling studies.
• Avian Services (Diagnostic, Regulatory Testing, Custom Biologics) Service portfolio covering avian diagnostic and regulatory testing, IgY antibody services, and custom biologics and vaccine manufacturing support for veterinary and human health customers.

Quantifiable outcome

• 10 antibodies with supported development entered clinical trials
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• RoukenBiocoreStrategic or Co-development Partner · 17 February 2026Strategic partnership announced February 17, 2026, integrating AVS Bio's antibody discovery and development services with RoukenBio's mechanism-driven functional characterization using cell-based and primary immune cell assay systems. Creates an end-to-end antibody engine combining AVS Bio's design-focused discovery platforms with RoukenBio's immunology expertise. Aims to improve lead candidate prioritisation and reduce translational uncertainty before IND-enabling studies.
• Scaler MarketingminorOthersWebsite development and marketing services partner credited in website footer.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Charles River Laboratories: Charles River Laboratories was AVS Bio's former parent company and remains a direct competitor in SPF egg production, animal health biological materials, and biologics services. Charles River's broader portfolio and global scale make it the most direct large-scale competitor in AVS Bio's core markets.
• GenScript: GenScript is a major contract service provider offering gene synthesis, protein expression, and antibody discovery services that directly compete with AVS Bio's rPEx® platform and multi-platform antibody discovery offering. Both serve biopharma and biotech customers with similar end-to-end workflows.
• Bio-Techne: Bio-Techne is a major supplier of research antibodies, recombinant proteins, and related reagents that directly competes with AVS Bio's catalog antibodies and proteins business. Both serve global biopharma research customers with similar protein and antibody product portfolios.
• Abcam: Abcam is a leading supplier of research antibodies and related reagents that directly competes with AVS Bio's catalog antibody offerings. The connection is reinforced by AVS Bio CEO Jac Price's prior SVP role at Abcam.
• Cell Signaling Technology: Cell Signaling Technology is a leading provider of highly validated research antibodies that directly competes with AVS Bio's catalog antibody business. Both serve the same life sciences research and biopharma development customer base.
• Bio-Rad Laboratories: Bio-Rad's Life Science segment offers antibodies, proteins, and bioprocessing products that compete directly with AVS Bio's catalog products. Both companies serve global biopharma and academic research customers with similar reagent and instrument offerings.

Broad incumbents

• Lonza: Lonza is a large CDMO offering comprehensive biologics manufacturing, antibody production, and cell line development services that overlap with AVS Bio's protein production and antibody discovery offerings. As a global incumbent, Lonza competes for large biopharma accounts that AVS Bio also targets.
• Sartorius: Sartorius is a leading bioprocessing equipment and consumables supplier that competes with AVS Bio in the broader biologics production value chain. Sartorius serves many of the same biopharma customers and is expanding into adjacent services that overlap with AVS Bio's offerings.
• Eurofins Scientific: Eurofins provides bioanalytical testing, diagnostics, and biologics services that overlap with AVS Bio's avian testing services and antibody characterization offerings. Eurofins' global laboratory network competes for testing and characterization work from large biopharma customers.

Emerging players

• Creative Biolabs: Creative Biolabs is a CRO offering custom antibody discovery, engineering, and production services that directly compete with AVS Bio's antibody discovery and protein production business. Creative Biolabs focuses on niche biopharma customers with custom antibody engineering needs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/avsbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AVS Bio